ApconiX has joined the Medicines Discovery Catapult’s Virtual R&D platform.  This is a unique national network of consultants, private sector CROs, expert labs and public sector centres of excellence, providing medicines discovery expertise, services and virtual programme management.

ApconiX specialises in ion channel biology, target safety assessments and in all aspects of nonclinical programme design and delivery.  An exceptional team of world-renowned scientists with a wide range of expertise, ApconiX focuses on needs in a cost-effective and flexible way, supporting customers in nonclinical drug safety.

The ion channel laboratory works closely with the toxicology consultancy to bring together over 300 years of expertise in preclinical safety.   Dr Michael Morton, expert electrophysiologist, Co-founder and Director of ApconiX commented, “The unique combination of laboratory and consultancy means ApconiX offers expert interpretation of client data in the context of their drug discovery program, like no other provider can.”

ApconiX provides support to over 100 clients world-wide. “As we respond to the needs of our clients, we continue to grow significantly and to grow our portfolio. We are actively involved in novel research and are keen to progress scientific knowledge,” Mike continued.

The laboratory provides a quick turnaround time of all our high-quality hERG data, with over 80% of data being reported within one week.  This supports clients in their iterative chemical design within the timelines of the make-test cycle.  The full CiPA panel is becoming increasingly important, “as the CiPA initiative is deployed throughout Pharma, we have seen a ten-fold increase in our client’s requesting the CiPA ion channel panel over the past year” added Mike.

The laboratory also offers all the expertise needed to explore novel ion channels as drug targets.

“ApconiX is continually forming collaborative relationships, helping customers large and small. The changing face of drug discovery and development means a safe pair of hands is needed to help companies navigate what can be a challenging pathway towards safe, effective and profitable drugs,” remarked Professor Ruth Roberts, Director and Co-founder of ApconiX.